A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

This is a multicenter, open-label, 2-stage, single-arm efficacy and safety study.
Approximately 63 patients with histologically proven stage IIIc or stage IV melanoma who fail
to qualify for curative surgery and who bear one or more tumors that are accessible for
direct injections and at least one measurable lesion by RECIST 1.1 criteria will be
considered.

Prospective patients will attend the study center for initial screening within 28 days prior
to treatment with CVA21. They will have the nature of the study and its procedures and risks
fully explained. All patients must provide a written informed consent to participate in the
study.

The dose of CVA21 for this study is 3 x 108 TCID50 (about 4.5 x 106 TCID50/kg for a 70-kg
patient) by IT administration. Each patient will receive 4 separate CVA21 administrations in
the first 8 days on trial (Days 1, 3, 5 and 8), followed by a fifth dose 2 weeks later (Day
22) and further administrations at 3 weekly intervals (Days 43, 64, 85, 106 and 127, up to a
maximum of 10 sets of injections) or until confirmed disease progression or development of
excessive toxicity.

Disease status will be assessed by contrast-enhanced computerized tomography (CT) or magnetic
resonance imaging (MRI) scan and/or direct caliper measurement (and ultrasound assistance, if
necessary) and categorized by immune-related RECIST 1.1 criteria prior to commencing
treatment (baseline) and at Days 43, 85, 127 and 169 and 12-weekly intervals thereafter until
disease progression. At 2 years, intervals can increase to 6 months.

At 12 weeks post-commencement of treatment (Day 85), if a patient's disease status is classed
as progressive disease (but without rapid clinical deterioration) the patient may remain on
the trial for a further 6 weeks, when his/her disease status will be confirmed prior to the
scheduled treatment. If disease progression is confirmed, the patient will cease treatment
but will remain on the study and be observed for efficacy and safety until initiation of
treatment with non-CVA21 anticancer therapies. However, survival will be followed until
death. If stable disease or better (CR or PR) is observed at this time, the patient will
continue treatment as per the protocol. Complete and partial responses will be confirmed at
the next contrast-enhanced CT or MRI scan analysis.

Patients who have evidence of biologic activity, i.e., tumor inflammatory reaction and/or
stable disease or better, at 18 weeks (Day 127) are eligible to participate in the extension
trial in which they will continue to receive IT injections of CVA21 every 3 weeks up to a
total of 1 year of therapy from the first injection.

Throughout the trial, immunological responses to the tumor and CVA21 will be monitored.

After the full CVA21 injection schedule has been completed, patients will be followed at
12-weekly intervals beginning on Day 169 for a total of 12 months according to the schedule
for safety assessment and indefinitely for survival. Patients with progressive disease (but
without rapid clinical deterioration) at 6 months (Day 169) will have a further tumor
assessment 6 weeks later for confirmation or continuation of observation for duration of
disease control and all subjects will be followed for survival. Patients who are withdrawn
from treatment with CVA21 during the treatment phase must also be followed up every 6 weeks
for 12 weeks for safety and for survival.

Inclusion Criteria:

1. Patient with histologically proven stage IIIc or stage IV melanoma who fails to
qualify for curative surgery and who bears one or more tumors that are accessible for
direct injection

2. Patient must have had no more than one previous systemic regimen for management of
melanoma; however, adjuvant chemotherapy administered 6 months or longer before
entering the trial does not count as a line of treatment

3. Absence of circulating serum neutralizing antibodies to CVA21 (titer < 1:16)

4. At least one tumor 0.5 to 10 cm in the longest diameter must be suitable for injection
and at least one tumor must be equal to or greater than 1 cm and qualified to be a
target lesion for RECIST 1.1 criteria

5. Patient must have adequate hematologic, hepatic and renal function, defined as:

- Absolute neutrophil count (ANC) > 1.5 x 10^9/L, platelets > 100 x 10^9/L

- Bilirubin < 1.5 times the upper limit of normal (ULN), aspartate aminotransferase
(AST) < 2.5 x ULN

- Serum creatinine < 1.5 x ULN; if > 1.5 x ULN, it must be confirmed that
creatinine clearance > 30 mL/minute

6. Serum lactate dehydrogenase (LDH) levels < or = 1.5 x ULN

7. Male or female age 18 years or older

8. Performance status (Eastern Cooperative Oncology Group [ECOG]) 0 or 1

9. Estimated life expectancy of more than 6 months

10. Recovered from prior therapy with at least 4 weeks since the last exposure to
chemotherapy or radiotherapy

11. Patient is able and willing to provide written informed consent to participate in the
study

12. Fertile males and females must agree to the use of an adequate form of contraception,
e.g., condoms for males. A negative pregnancy test is required in female patients of
childbearing potential.

Exclusion Criteria:

1. Mucosal or ocular primary tumors

2. Bone metastases

3. Greater than 3 visceral metastases

4. Any visceral metastases > 10 cm

5. Serum anti-CVA21 neutralizing titer of > 1:16 at baseline

6. Presence of any central nervous system (CNS) tumor that has not been stable for at
least 3 months off corticosteroids and confirmed by imaging

7. Tumors to be injected lying in mucosal regions or close to an airway, major blood
vessel or spinal cord that, in the opinion of the Investigators, could cause occlusion
into a major vessel in the case of necrosis

8. Only measurable tumor had prior local radiotherapy without subsequent nodule
progression

9. Patient has received chemotherapy within the last 4 weeks prior to first injection

10. ECOG score greater than 1

11. Estimated life expectancy of less than 6 months

12. Pregnancy or breastfeeding

13. Primary or secondary immunodeficiency, including immunosuppressive disease, and
immunosuppressive doses of corticosteroids (e.g., prednisolone > 7.5 mg per day) or
other immunosuppressive medications including cyclosporine, azathioprine, interferons
within the past 4 weeks prior to screening

14. Positive serology for human immunodeficiency virus (HIV), hepatitis B or C

15. Full dose anticoagulation or a history of bleeding diathesis or poorly controlled
bleeding in the last month prior to screening

16. Previous splenectomy

17. Presence of uncontrolled infection

18. Presence of unstable neurological disease

19. Any uncontrolled medical condition that, in the opinion of the investigator, is likely
to place the patient at unacceptable risk during the study or reduce his/her ability
to complete the study

20. Participation in another study requiring administration of an investigational drug or
biological agent within the last 4 weeks prior to screening

21. Any other medical or psychological condition that would preclude participation in the
study or compromise ability to give informed consent

22. Participation in any previous melanoma immunotherapy trial within 1 month prior to
entry to this trial or any trial of any other investigational agent within the last
month prior to entry to this trial

23. Active infections or serious general medical conditions

24. Patients with previous malignancies should only be permitted if they have been in a
continued state of "no evidence of disease" for at least 5 years with the exception of
adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ (DCIS) of
the breast, and basal cell/squamous cell skin cancer

25. Known allergy to treatment medication or its excipients and/or to the contrast medium